Early Access Programmes (EAPs) provide the possibility of making medicines that address an unmet medical need available to patients before regulatory approval of the European Medicine Agency. Market Access includes market development activities and patient access strategy, EAPs can positively impact both areas. The aim of this review is to consider, compile and describe the main EAPs available in Europe. METHODS: We conducted a review and performed a mapping of EAPs systems that exists in Europe. We searched existing literature in Embase, National Health Systems Website, ISPOR conference websites and Internet. In the countries where information were more scattered we directly contacted regulatory agencies and clinicians familiar with the local EAP regulations and practices. RESULTS: We described the practical implications surrounding the regulatory framework for EAPs, the key stakeholders involved in EAP decision-making and administration, the timelines for EAPs approval, and the key factors for success. Many countries do not have an EAP in place and compassionate use is the only route to market for unregistered or investigational products. This is the case for Germany, Belgium, Poland, Austria and Switzerland. The markets where EAP are more developed and sales are possible are: France, Spain, UK, Italy, Sweden, Denmark, Portugal, and Norway. CONCLUSIONS: This project made specific recommendations on the most favourable countries, based on the ease of setting up such a programme and the potential revenue that could result. At the time, there were several countries where the legal framework was changing (e.g. Austria) and some markets where information was simply not available. 
PHP148 EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY: DIFFERENCES BETWEEN PHARMACEUTICAL COMPANIES' CLAIMS AND IQWIG BENEFIT ASSESSMENTS
Roche Pharma, Germany, 2 German Association of Research-based Pharmaceutical Companies (vfa) , Berlin, Germany, 3 Hannover Medical School, Hannover, Germany OBJECTIVES: Since January 2011 the new German AMNOG health care reform includes a mandatory EBA for innovative medicines. At time of launch pharmaceutical companies have to submit a benefit dossier which is subsequently evaluated by the Institute for Quality and Efficiency in Health Care (IQWiG). Our aim was to explore differences in companies' benefit claims and the respective IQWiG assessments. METHODS: The review includes EBAs that were started in 2011. The Joint Federal Committee's (GBA) webpage was used to obtain the respective companies' benefit claims and IQWiG overall (i.e. aggregated, not on endpoint level) benefit assessments. The GBA's official scale is discriminating six levels of additional benefit versus comparative treatment: 1: major; 2: significant; 3: marginal; 4: not quantifiable; 5: no benefit; 6: less benefit. IQWiG's official evidence categories include: 1: proof; 2: indication; 3: hint. For the purpose of this abstract always the highest benefit level and evidence category claimed/assessed was taken into account. RESULTS: Twenty-four EBAs were started in 2011: Tafamidis Meglumin, Telaprevir, Abirateronacetat, Linagliptin, Pirfenidon, Boceprevir, Bromfenac, Ipilimumab, Fampridin, Belimumab, Belatacept, Dexmedetomidin, Cannabis Sativa, Apixaban, Pitavastatin, Retigabin, Aliskiren/Amlodipin, Collagenase, Eribulin, Cabazitaxel, Fingolimod, Regadenoson, Ticacrelor, Olmesartan/Amlodipin/Hydrochlorthiazid. The companies' benefit claims/IQWiG benefit assessments included the benefit level: major in 11/0 EBAs; significant 4/4; marginal 0/3; not quantifiable 1/2; no benefit 1/8; less benefit 0/0. Two Orphan indications were excluded from this analysis; for five drugs no full dossier submissions and/or IQWiG assessments were conducted (Bromfenac; Dexmedetomidin; Pitavastatin; Regadenoson; Olmesartan/Amlodipin/Hydrochlorthiazid) which resulted in a 'no benefit' conclusion by the GBA. Companies claimed a proof in thirteen EBAs. IQWiG acknowledged a proof in three EBAs. CONCLUSIONS: Both, evidence and benefit levels show major differences between companies' claims and IQWiG assessments. Most frequently companies claimed a major benefit (11 EBAs) while IQWiG most frequently applied the 'no benefit' category (8 EBAs).
PHP149 HEALTH TECHNOLOGY ASSESSMENT EVIDENCE CRITERIA: WHAT TYPES OF EVIDENCE SHOULD BE PRESENTED FOR PRODUCTS USED TO SCREEN FOR DISEASE IN THE UNITED STATES?
McGee NM Lash Group, San Bruno, CA, USA OBJECTIVES: Screening technologies are on the forefront of innovation and have an impact on the care of patients in terms of identifying disease and appropriate treatment options at an early stage. As such, screening technologies are of key interest to health technology assessment (HTA) agencies in the United States (US) and abroad. The objective of this research study is to evaluate existing technology assessment standards for screening technologies in order to establish a best practice that may be implemented by US technology assessment organizations to broaden the criteria used in assessments for screening products. METHODS: Qualitative interviews involving 12 HTA experts from the US, Canada, and the UK were conducted. The experts represented HTA organizations that were for profit, not for profit, government agencies, private payers, and academic medical centers. While quantitative analysis of the levels of evidence required by HTA organizations for screening products would produce a desirable study design, the findings from the literature review indicated that quantitative evidence does not exist. RESULTS: The results of this study indicate that the best practices should include criteria to support screening reliability, sensitivity and specificity; evaluate data to identify appropriate patient populations; reference to the natural course of the disease; consider ethical implications; and the impact of cost. CONCLUSIONS: HTA criteria specific to the evaluation of screening products would positively impact HTA stakeholders such as HTA organizations, their clients, patients, as well as technology innovators. Best practices designed to help HTA organizations choose criteria that are focused on screening technologies will help to identify whether relevant patient populations for the technology exist. In so doing, levels of evidence and data requirements would be more transparent to screening technology innovators and patients. Cost should be a part of the assessment to understand the cost and benefit of using the product in specific patient populations for appropriate clinical decision making. 
PHP150 SEARCHING FOR A THRESHOLD IN HUNGARY

OBJECTIVES:
Estimating the critical threshold value from previous reimbursement decisions is one of the several methods to determine a cost effectiveness threshold. The methodology is based on analyzing the relationship between the Incremental Cost Effectiveness Ratio (ICER) of the assessed health technologies, and the reimbursement decisions. Our study tries to examine if there is any relationship between cost effectiveness and decision making in Hungary by analyzing data abstracted from HTA appraisals and health economic studies. METHODS: The members of the HTA Department examined the submissions containing a costutility analysis which were assessed by the Hungarian HTA Office since 2004. We created a database in which we summed up the cost/QALY values of the examined submissions and HTA reports. We analyzed the appraisal determinations of the HTA Committee regarding the assessed submissions in order to examine the likelihood of a positive/negative decision according the level of the assessed pharmaceutical's ICER value. We searched for the technology with the highest ICER value, which got reimbursed. RESULTS: We examined 165 submissions which contained a cost-utility analysis that have arrived to our Department. Our results suggest that there is only a weak correlation (rϭ0,14) between the level of the calculated ICER and the reimbursement decisions. We found, that the highest ICER which resulted a positive reimbursement decision was 9 500 000 HUF/QALY (32 000 EUR). CONCLUSIONS: One of the several methods to determine a threshold value is to examine the relationship between previous reimbursement decisions and ICER values calculated in health economic appraisals. However one must take into account, that estimating a threshold value based on prior decisions has limitations, as reimbursement decisions are almost never made based on ICER ratios alone. This could be the main reason our study only showed a weak correlation between the level of calculated ICERs and the outcomes of the determinations. 
PHP151 THE INFLUENCE OF PATIENT COMPLIANCE ARGUMENTS IN NICE TECHNOLOGY APPRAISALS
OBJECTIVES:
To identify, using HTAinSite, if and how manufacturers have used improved patient compliance as a value argument for their product in submissions to the National Institute for Health and Clinical Excellence (NICE). We analysed if and how compliance data were presented, how they were received by NICE, and if they were an influential factor in NICE's decision making. METHODS: A key phrase search in HTAinSite was used to identify instances of 'compliance' and 'adherence' in manufacturer submissions and NICE technology appraisal (TA) documents. After review for relevance, information was extracted and used to conduct a qualitative analysis. RESULTS: Fifteen manufacturer's submissions and 12 TAs reported an improvement in compliance as a value argument for their drug. Factors used to justify improved compliance included improved convenience, a reduction in adverse events, increased treatment choice, and improved route of administration. In 8 of 13 TAs (relating to 11 manufacturer submissions), NICE state that the compliance argument was considered by the Committee. In the remaining 5 TAs, despite inclusion of a compliance argument by manufacturers in their submissions, the Committee made no reference to it in the TA. Interestingly, only three manufacturers explicitly reported evidence supporting their compliance argument; however, the Committee discussed this in all of the associated TAs. The impact of improved compliance on clinical outcomes or cost-effectiveness was frequently not clearly reported by manufacturers or NICE. NICE did not explicitly cite compliance as an influential factor in their final decision in any TAs. CONCLUSIONS: The committee are more likely to consider a compliance argument if there is a clear clinical rationale and it is accompanied by supporting data. Although compliance arguments are considered by the Committee, NICE have not explicitly stated to have used them to influence final decisions.
PHP152 THE EARLY BENEFIT ASSESSMENT OF DRUGS THAT ARE LAUNCHED BEFORE 2011
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